Boundless Bio Inc (NASDAQ: BOLD) is a clinical-stage oncology company that discovers and develops small molecule drugs targeting extrachromosomal DNA (ecDNA) biology in cancer cells. The company has no product revenue and funds operations through equity offerings, debt financings, and potential collaboration or licensing arrangements. Boundless Bio uses its proprietary Spyglass platform to identify targets essential for ecDNA function in oncogene amplified tumors, then designs drug candidates it calls ecDNA-directed therapeutics (ecDTx) intended to be synthetic lethal in cancer cells reliant on ecDNA amplification biology. Its lead program, BBI-940, is designed to degrade a kinesin protein critical to ecDNA segregation, with initial focus on FGFR1 amplified ER+/HER2- breast cancer and a subtype of triple-negative breast cancer called TNBC-LAR. A prior program, BBI-355, a CHK1 inhibitor evaluated in the POTENTIATE Phase 1/2 trial, was discontinued in May 2025 after interim results. Net cash inflow from investing activities was approximately $37.8 million for the year ended December 31, 2025, driven by maturities of investment securities.

Revenue model

No product revenue as of FY2025. The company finances operations through equity issuances, including an at-the-market sales agreement, debt financings, and potential future collaboration or licensing arrangements. The 2024 Employee Stock Purchase Plan and stock option exercises contributed minimal cash of $0.1 million in financing activities during FY2025.

Products and services

BBI-940: a small molecule designed to degrade a kinesin protein critical to ecDNA segregation, targeting FGFR1 amplified ER+/HER2- breast cancer and TNBC-LAR (as of the 10-K filed 2026-03-09). BBI-355: an oral selective CHK1 inhibitor evaluated in the POTENTIATE Phase 1/2 trial, discontinued in May 2025. Spyglass: proprietary discovery platform used to interrogate ecDNA biology and identify synthetic lethality targets in oncogene amplified cancers.

Customers and end markets

No commercial customers as of FY2025. End market is patients with oncogene amplified cancers, specifically those whose tumors rely on ecDNA amplification biology. Initial clinical focus includes FGFR1 amplified ER+/HER2- breast cancer and TNBC-LAR, a subtype representing approximately 10 to 15% of triple-negative breast cancers.

Value-chain role

Preclinical and clinical-stage drug discoverer and developer. The company identifies biological targets using its Spyglass platform, designs small molecule drug candidates internally, and conducts clinical trials. It has no manufacturing or commercial infrastructure disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-09

Industry: Pharmaceutical Preparations Peers: Actinium Pharmaceuticals Inc Cellectar Biosciences Inc Genelux Corp Instil Bio Inc Precision BioSciences Inc Spero Therapeutics Inc T2 Biosystems, Inc. Fibrobiologics Inc